Lercanidipinhydrochlorid Rivopharm

Lercanidipine Hydrochloride, the active ingredient in Lercanidipinhydrochlorid Rivopharm, is a dihydropyridine calcium‑channel blocker presented as an oral tablet for systemic administration. It is used to lower elevated blood pressure in adult patients with primary hypertension, helping to reduce cardiovascular risk.

GNH USA supplies Lercanidipinhydrochlorid Rivopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Lercanidipine Hydrochloride is a calcium‑channel blocker indicated for the management of hypertension, acting on the vascular smooth‑muscle tone to achieve blood‑pressure control.

Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension.

Lercanidipine is generally well tolerated, but patients may experience adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially upon standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or urticaria. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, clinicians should consider several safety aspects.

Monitor blood pressure: check regularly to ensure therapeutic response. Avoid abrupt discontinuation: taper dose if therapy must be stopped. Caution in hepatic impairment: dose adjustment may be required. Use with caution in the elderly: increased sensitivity to blood‑pressure changes. Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. Store at room temperature: keep in the original container, protect from moisture.

Lercanidipine may interact with other medicines, necessitating careful review.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives: additive blood‑pressure lowering effect. - Grapefruit juice: can raise drug exposure. - Diuretics: risk of electrolyte imbalance and excessive blood‑pressure reduction.